175 related articles for article (PubMed ID: 33660007)
41. Prognostic superiority of the National Comprehensive Cancer Network International Prognostic Index over pretreatment whole-body volumetric-metabolic FDG-PET/CT metrics in diffuse large B-cell lymphoma.
Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC
Eur J Haematol; 2015 Jun; 94(6):532-9. PubMed ID: 25311082
[TBL] [Abstract][Full Text] [Related]
42. Diffuse large cell lymphomas: identification of prognostic factors and validation of the International Non-Hodgkin's Lymphoma Prognostic Index. A Hellenic Cooperative Oncology Group Study.
Nicolaides C; Fountzilas G; Zoumbos N; Skarlos D; Kosmidis P; Pectasides D; Karabelis A; Giannakakis T; Symeonidis A; Papadopoulos A; Antoniou F; Pavlidis N
Oncology; 1998; 55(5):405-15. PubMed ID: 9732217
[TBL] [Abstract][Full Text] [Related]
43. Presence of a high-grade component in gastric mucosa-associated lymphoid tissue (MALT) lymphoma is not associated with an adverse prognosis.
Ang MK; Hee SW; Quek R; Yap SP; Loong S; Tan L; Tao M; Lim ST
Ann Hematol; 2009 May; 88(5):417-24. PubMed ID: 18777110
[TBL] [Abstract][Full Text] [Related]
44. Prognostic indices in diffuse large B-cell lymphoma in the rituximab era: an analysis of the UK National Cancer Research Institute R-CHOP 14 versus 21 phase 3 trial.
Gleeson M; Counsell N; Cunningham D; Lawrie A; Clifton-Hadley L; Hawkes E; McMillan A; Ardeshna KM; Burton C; Chadwick N; Gambell J; Smith P; Mouncey P; Pocock C; Radford J; Davies J; Turner D; Kruger A; Johnson P; Linch D
Br J Haematol; 2021 Mar; 192(6):1015-1019. PubMed ID: 32436212
[TBL] [Abstract][Full Text] [Related]
45. Evaluation of clinical and biological prognostic factors in relapsed or refractory diffuse large B-cell lymphoma patients after previous treatment with rituximab and chemotherapy: results of the PRO-R-IPI study.
Panizo C; Rodríguez AJ; Gutiérrez G; Díaz FJ; González-Barca E; de Oña R; Grande C; Sancho JM; García-Álvarez MF; Sánchez-González B; Peñalver FJ; Cannata J; Espeso M; Requena MJ; Gardella S; Durán S; González AP; Alfonso A; Caballero MD;
Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):398-403. PubMed ID: 25843416
[TBL] [Abstract][Full Text] [Related]
46. A modified scoring of the NCCN-IPI is more accurate in the elderly and is improved by albumin and β2 -microglobulin.
Melchardt T; Troppan K; Weiss L; Hufnagl C; Neureiter D; Tränkenschuh W; Hopfinger G; Magnes T; Deutsch A; Neumeister P; Hackl H; Greil R; Pichler M; Egle A
Br J Haematol; 2015 Jan; 168(2):239-45. PubMed ID: 25236324
[TBL] [Abstract][Full Text] [Related]
47. [Comparison of prognostic models for patients with early-stage diffuse large B-cell lymphoma].
Liu W; Wang X; Zhang C; Xie Y; Lin N; Tu M; Ping L; Ying Z; Deng L; Huang H; Wu M; Sun Y; Du T; Leng X; Ding N; Zheng W; Song Y; Zhu J
Zhonghua Xue Ye Xue Za Zhi; 2016 Apr; 37(4):269-72. PubMed ID: 27093984
[TBL] [Abstract][Full Text] [Related]
48. Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma.
Xu-Monette ZY; Li L; Byrd JC; Jabbar KJ; Manyam GC; Maria de Winde C; van den Brand M; Tzankov A; Visco C; Wang J; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; Huh J; Ponzoni M; Ferreri AJ; Møller MB; Parsons BM; Winter JN; Wang M; Hagemeister FB; Piris MA; Han van Krieken J; Medeiros LJ; Li Y; van Spriel AB; Young KH
Blood; 2016 Dec; 128(26):3083-3100. PubMed ID: 27760757
[TBL] [Abstract][Full Text] [Related]
49. Clinicopathological analysis of oral plasmablastic lymphoma: A systematic review.
Rodrigues-Fernandes CI; de Souza LL; Santos-Costa SFD; Silva AMB; Pontes HAR; Lopes MA; de Almeida OP; Brennan PA; Fonseca FP
J Oral Pathol Med; 2018 Nov; 47(10):915-922. PubMed ID: 29917262
[TBL] [Abstract][Full Text] [Related]
50. Hyperfibrinogenemia is a poor prognostic factor in diffuse large B cell lymphoma.
Niu JY; Tian T; Zhu HY; Liang JH; Wu W; Cao L; Lu RN; Wang L; Li JY; Xu W
Ann Hematol; 2018 Oct; 97(10):1841-1849. PubMed ID: 29860562
[TBL] [Abstract][Full Text] [Related]
51. The highest prognostic impact of LDH among International Prognostic Indices (IPIs): an explorative study of five IPI factors among patients with DLBCL in the era of rituximab.
Park JH; Yoon DH; Kim DY; Kim S; Seo S; Jeong Y; Lee SW; Park CS; Huh J; Suh C
Ann Hematol; 2014 Oct; 93(10):1755-64. PubMed ID: 25027115
[TBL] [Abstract][Full Text] [Related]
52. Application of the international prognostic index in a study of Chinese patients with non-Hodgkin's lymphoma and a high incidence of primary extranodal lymphoma.
Mok TS; Steinberg J; Chan AT; Yeo WM; Hui P; Leung TW; Johnson P
Cancer; 1998 Jun; 82(12):2439-48. PubMed ID: 9635538
[TBL] [Abstract][Full Text] [Related]
53. Improved prognostic stratification using NCCN- and GELTAMO-international prognostic index in patients with diffuse large B-cell lymphoma.
Hong J; Kim SJ; Chang MH; Kim JA; Kwak JY; Kim JS; Yoon DH; Lee WS; Do YR; Kang HJ; Eom HS; Park Y; Won JH; Mun YC; Kim HJ; Kwon JH; Kong JH; Oh SY; Lee S; Bae SH; Yang DH; Jun HJ; Lee HS; Yun HJ; Lee SI; Kim MK; Yi JH; Lee JH; Kim WS; Suh C
Oncotarget; 2017 Nov; 8(54):92171-92182. PubMed ID: 29190906
[TBL] [Abstract][Full Text] [Related]
54. Useful prognostic tools based on complete blood cell counts in diffuse large B-cell lymphoma.
Shimono J; Takahashi S; Takemura R; Kakinoki Y
Int J Lab Hematol; 2019 Dec; 41(6):754-761. PubMed ID: 31529774
[TBL] [Abstract][Full Text] [Related]
55. Prognostic significance of the immunophenotype versus the International Prognostic Index in aggressive non-Hodgkin's lymphoma.
Intragumtornchai T; Rotnakkarin P; Sutcharitchan P; Wannagrairoj P
Clin Lymphoma; 2003 Jun; 4(1):52-5. PubMed ID: 12837156
[TBL] [Abstract][Full Text] [Related]
56. Red blood cell distribution width and platelet counts are independent prognostic factors and improve the predictive ability of IPI score in diffuse large B-cell lymphoma patients.
Li M; Xia H; Zheng H; Li Y; Liu J; Hu L; Li J; Ding Y; Pu L; Gui Q; Zheng Y; Zhai Z; Xiong S
BMC Cancer; 2019 Nov; 19(1):1084. PubMed ID: 31711453
[TBL] [Abstract][Full Text] [Related]
57. A diachronic-comparative analysis for the identification of the most powerful prognostic index for localized diffuse large B-cell lymphoma.
Mian M; Marcheselli L; Rossi A; Visco C; Chiappella A; Volpetti S; Zaja F; Mondello P; Fiegl M; Billio A; Federico M; Luminari S; Rambaldi A; Cortelazzo S
Ann Oncol; 2014 Dec; 25(12):2398-2404. PubMed ID: 25274614
[TBL] [Abstract][Full Text] [Related]
58. Refractory plasmablastic lymphoma-a review of treatment options beyond standard therapy.
Pretscher D; Kalisch A; Wilhelm M; Birkmann J
Ann Hematol; 2017 Jun; 96(6):967-970. PubMed ID: 28011983
[TBL] [Abstract][Full Text] [Related]
59. A Case of Plasmablastic Lymphoma Achieving Complete Response and Durable Remission after Lenalidomide-Based Therapy.
Schmit JM; DeLaune J; Norkin M; Grosbach A
Oncol Res Treat; 2017; 40(1-2):46-48. PubMed ID: 28095384
[TBL] [Abstract][Full Text] [Related]
60. Prognostic impact of sarcopenia in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
Go SI; Park MJ; Song HN; Kim HG; Kang MH; Lee HR; Kim Y; Kim RB; Lee SI; Lee GW
J Cachexia Sarcopenia Muscle; 2016 Dec; 7(5):567-576. PubMed ID: 27104110
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
